These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Spotlight on paroxetine in psychiatric disorders in adults. Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788 [TBL] [Abstract][Full Text] [Related]
46. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105 [TBL] [Abstract][Full Text] [Related]
47. Effect of nortriptyline and paroxetine on measures of chaos of heart rate time series in patients with panic disorder. Yeragani VK; Rao R J Psychosom Res; 2003 Dec; 55(6):507-13. PubMed ID: 14642980 [TBL] [Abstract][Full Text] [Related]
48. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813 [TBL] [Abstract][Full Text] [Related]
49. Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship? Butters MA; Bhalla RK; Mulsant BH; Mazumdar S; Houck PR; Begley AE; Dew MA; Pollock BG; Nebes RD; Becker JT; Reynolds CF Am J Geriatr Psychiatry; 2004; 12(4):387-94. PubMed ID: 15249276 [TBL] [Abstract][Full Text] [Related]
50. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Cassano GB; Puca F; Scapicchio PL; Trabucchi M; J Clin Psychiatry; 2002 May; 63(5):396-402. PubMed ID: 12019663 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Yu YM; Gao KR; Yu H; Shen YF; Li HF J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. Ushiroyama T; Ikeda A; Ueki M J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873 [TBL] [Abstract][Full Text] [Related]
53. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W; Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199 [TBL] [Abstract][Full Text] [Related]
54. Selective serotonin reuptake inhibitors and the tricyclic antidepressant nortriptyline in the treatment of post stroke depression. Hackett M; Anderson C; House A Top Stroke Rehabil; 2004; 11(1):viii; author reply ix. PubMed ID: 15000073 [No Abstract] [Full Text] [Related]
55. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Tucker P; Zaninelli R; Yehuda R; Ruggiero L; Dillingham K; Pitts CD J Clin Psychiatry; 2001 Nov; 62(11):860-8. PubMed ID: 11775045 [TBL] [Abstract][Full Text] [Related]
57. Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder. Yeragani VK; Pohl R; Jampala VC; Balon R; Ramesh C; Srinivasan K Depress Anxiety; 2000; 11(3):126-30. PubMed ID: 10875054 [TBL] [Abstract][Full Text] [Related]
58. Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Chiu HJ; Hong CJ; Chan CH Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jun; 57(6):418-23. PubMed ID: 8803304 [TBL] [Abstract][Full Text] [Related]